Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report

Solid tumors harboring BRCA1 or BRCA2 mutations have been shown to respond to PARP inhibitors. These responses are partial and transient. In this case report, we describe an 82-year-old male with poorly differentiated prostate cancer with metastases to the lung, liver, abdomen, and bowel. Molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: VanderWeele, David J., Paner, Gladell P., Fleming, Gini F., Szmulewitz, Russell Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4510409/
https://www.ncbi.nlm.nih.gov/pubmed/26258074
http://dx.doi.org/10.3389/fonc.2015.00169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4510409/
https://www.ncbi.nlm.nih.gov/pubmed/26258074
http://dx.doi.org/10.3389/fonc.2015.00169

Ejemplares similares